February 25, 2021 01:44 PM ESTUpdated 02:35 PM

Avid Bioservices, with recent IPO and Covid-19 partnership in hand, launches 2nd phase of facility expansion

Conner Mitchell

California’s Avid Bioservices now has two simultaneous expansion projects underway as the CDMO’s projections for customer demand sparked the launch this week of the second …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Avid Bioservices, with recent IPO and Covid-19 partnership in hand, launches 2nd phase of facility expansion

Conner Mitchell

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Avid Bioser­vices, with re­cent IPO and Covid-19 part­ner­ship in hand, launch­es 2nd phase of fa­cil­i­ty ex­pan­sion

Conner Mitchell

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Avid Bioservices, with recent IPO and Covid-19 partnership in hand, launches 2nd phase of facility expansion

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks